Clinical trials: Solid Tumors, completed
Solid Tumors
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.
- Trial name
- ASONEP (NCT00661414)
- Testing
- ASONEP (sonepcizumab/LT1009)
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Lpath, Inc.
Cachexia, Depression
Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer
RATIONALE: A computer-based system for assessing symptoms may be effective for patients with metastatic or advanced cancer. PURPOSE: This clinical trial is studying how well computerized questionnaires work in assessing symptoms…
- Conditions
- Cachexia, Depression, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00972634
- Testing
- computer-assisted intervention, questionnaire administration, assessment of therapy complications
- Where
- Norway
- Volunteers
- 1,051 people
- Sponsor
- Norwegian University of Science and Technology
Renal Cancer, Tumor, Solid
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.
- Conditions
- Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor
- Trial name
- CAIN (NCT05432232)
- Testing
- HistoSonics Investigational System
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- HistoSonics, Inc.
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization.
- Conditions
- Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT04439006
- Testing
- Best Practice, Ibrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jennifer Woyach
Advanced Solid Tumors
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased…
- Trial name
- HLX07Ib/II (NCT03577704)
- Testing
- HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumors
Study of DMXAA (Now Known as ASA404) in Solid Tumors
This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.
- Trial name
- DMXAA (NCT00863733)
- Testing
- DMXAA
- Volunteers
- 63 people
- Sponsor
- Cancer Research UK
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Primary objectives: To evaluate the safety and tolerability of BAT1006 in patients with advanced her2-positive solid tumors. To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
- Trial name
- NCT05414136
- Testing
- BAT1006
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Bio-Thera Solutions
Solid Tumours, Bone Metastasis
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Osteonecrosis of the Jaw (ONJ) is an adverse effect of antiresorptive therapy that is well-recognized in patients with advanced cancer.
- Trial name
- NCT01998607
- Testing
- Physician Survey
- Volunteers
- 420 people
- Sponsor
- Amgen
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)
This study of MK-8776 (SCH 900776) will evaluate its safety and tolerability when given as monotherapy or in combination with gemcitabine to participants with advanced solid tumors or lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms
- Trial name
- NCT00779584
- Testing
- MK-8776, Gemcitabine
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer.
- Trial name
- NCT04147234
- Testing
- BI 1387446 50 μg, BI 754091, BI 1387446 100 μg
- Where
- 8 sites in United States, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Metastatic Cancer
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD or MAD, PK, and PD of TJ210001 in subjects with relapsed or refractory advanced solid tumors.
- Conditions
- Solid Tumor, Metastatic Cancer, Advanced Cancer
- Trial name
- NCT04678921
- Testing
- TJ210001
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- I-Mab Biopharma US Limited
Advanced Solid Tumors, Lymphomas
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
- Trial name
- NCT00592163
- Testing
- ZIO-101-C (Darinaparsin)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Alaunos Therapeutics
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
This study consists of two Parts. Part A (Food Effect Study) and Part B (Determination of Maximum Tolerated Dose [MTD] for twice daily [BID] Dosing).Part A will be initiated first, and Part B will be initiated after the PK…
- Trial name
- NCT01773421
- Testing
- E7820
- Where
- 6 sites in Netherlands, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Cancer, Neoplasms
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
The purpose of this study is to determine the maximum tolerated dose of Debio 0932 when administered orally, every-other-day or daily during the first 30 days, in patients with solid tumours or lymphoma.
- Conditions
- Cancer, Neoplasms, Solid Tumors, Lymphoma
- Trial name
- NCT01168752
- Testing
- Debio 0932
- Where
- 3 sites in France
- Volunteers
- 81 people
- Sponsor
- Debiopharm International SA
Unspecified Adult Solid Tumor, Protocol Specific
High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer
RATIONALE: Brassica juncea that contains high amounts of selenium may slow the growth of cancer cells. Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of cancer cells…
- Trial name
- NCT00547547
- Testing
- high-selenium Brassica juncea, capecitabine, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Adenocarcinoma, Gastric Cancer
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
This is a research study for patients that have an advanced cancer that is confined mostly to the abdominal cavity and have failed treatment with conventional therapy, or for which no standard treatment exists.
- Trial name
- NCT00183859
- Testing
- irinotecan
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.